Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D’Silva of B. Riley Securities on Wednesday, January 20, 2021 at 10:30 am ET. B. Riley is limiting the live audience to institutional investors, investor relations, and employees of each presenting company. Private investors will not be given access to … [Read more…]

Stanton Optical Opens New Store in Onalaska, WI Area

Focused on Affordable and Accessible Eye Care, New Business to Serve Optical Needs of the Community ONALASKA, Wis.–(BUSINESS WIRE)–Stanton Optical, a leading full-service optical retailer offering accessible and affordable eye care and eyewear, opened its newest location in Onalaska on Monday, January 4. Located at 9362 State Rd 16, the new store marks Stanton Optical’s … [Read more…]

Feinstein Institutes Awarded More Than $4M to Research Perinatal Depression

MANHASSET, N.Y.–(BUSINESS WIRE)–To study perinatal depression in women – before and after childbirth – and possible new treatments, The Feinstein Institutes for Medical Research has been awarded more than $4 million in multi-year grants. The research will be led by Kristina Deligiannidis, MD, associate professor at the Feinstein Institutes’ Institute of Behavioral Science. The National … [Read more…]

Bluma Wellness Announces Proposed Warrant Repricing and Redemption of Debentures

TORONTO–(BUSINESS WIRE)–Bluma Wellness Inc. (the “Company”) (CSE: BWEL.U) (OTCQX:BMWLF) announces today that it proposes to amend the exercise price of up to 45,869,475 common share purchase warrants of the Company (collectively, the “Warrants”) to a price of US$1.01 per common share in the capital of the Company (each a “Common Share”), representing the closing price … [Read more…]

Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for … [Read more…]

Navitus Health Solutions Launches Program to Help Members Overcome Challenges Along the Prescription Journey

MADISON, Wis.–(BUSINESS WIRE)–Navitus Health Solutions, a full pass-through pharmacy benefit manager (PBM), today launched its Clinical Engagement Center designed to improve medication adherence and reduce both member and plan prescription costs, while easing benefit transitions. This three-pronged solution consists of Medication Therapy Management, Academic Detailing and Personalized Member Transitions to help health plans, providers and … [Read more…]

Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021. Chief Executive Officer, Greg Merril, is scheduled … [Read more…]

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

– Data Presented at the 2021 ASCO GI Cancers Symposium – BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination with IMFINZI® (durvalumab), … [Read more…]

Columbia Care Receives Provisional License for Adult Use at its Patriot Care Dispensary in Downtown Boston

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) announced today it was awarded a provisional license from the Massachusetts Cannabis Control Commission for adult use retail sales at its medical marijuana dispensary, operated under Patriot Care, at 21 Milk Street in downtown Boston. In December, … [Read more…]

Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels An injection procedure-related dose-limiting toxicity of urinary tract … [Read more…]